Karin Jooss Buys Shares of Fate Therapeutics, Inc. $FATE
Key Points
- Karin Jooss bought 87,900 shares of Fate Therapeutics, Inc. ($FATE).
- $FATE last traded around $2.06.
Karin Jooss, insider at Fate Therapeutics, Inc. ($FATE), bought 87,900 shares at an average price of $0.00. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Fate Therapeutics, Inc. ($FATE) Stock
Fate Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.